vs
MIMEDX GROUP, INC.(MDXG)とRepay Holdings Corp(RPAY)の財務データ比較。上の社名をクリックして会社を切り替えられます
MIMEDX GROUP, INC.の直近四半期売上が大きい($118.1M vs $78.6M、Repay Holdings Corpの約1.5倍)。MIMEDX GROUP, INC.の純利益率が高く(12.9% vs -178.3%、差は191.2%)。MIMEDX GROUP, INC.の前年同期比売上増加率が高い(27.1% vs 0.4%)。過去8四半期でMIMEDX GROUP, INC.の売上複合成長率が高い(18.1% vs -1.3%)
MiMedxは米国ジョージア州マリエッタに本拠を置く生物医療企業で、2008年に設立されました。胎盤、羊膜、臍帯といった分娩時の組織を原料として、皮膚移植手術に用いる医療用人工真皮を開発・製造し、再生医療分野で事業を展開しています。
Repay Holdings Corpは北米を主要市場とする決済テクノロジー企業で、小売、医療、自動車サービス、電子商取引などの業種の企業向けに、クレジット・デビットカード決済処理、ACH送金、POSシステム連携を含む統合決済ソリューションを提供し、顧客の業務効率化を支援しています。
MDXG vs RPAY — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | ||
|---|---|---|
| 売上 | $118.1M | $78.6M |
| 純利益 | $15.2M | $-140.1M |
| 粗利率 | 83.9% | 74.2% |
| 営業利益率 | 17.8% | -182.2% |
| 純利益率 | 12.9% | -178.3% |
| 売上前年比 | 27.1% | 0.4% |
| 純利益前年比 | 104.2% | -3304.1% |
| EPS(希薄化後) | $0.10 | $-1.68 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $118.1M | $78.6M | ||
| Q3 25 | $113.7M | $77.7M | ||
| Q2 25 | $98.6M | $75.6M | ||
| Q1 25 | $88.2M | $77.3M | ||
| Q4 24 | $92.9M | $78.3M | ||
| Q3 24 | $84.1M | $79.1M | ||
| Q2 24 | $87.2M | $74.9M | ||
| Q1 24 | $84.7M | $80.7M |
| Q4 25 | $15.2M | $-140.1M | ||
| Q3 25 | $16.7M | $-6.4M | ||
| Q2 25 | $9.6M | $-102.3M | ||
| Q1 25 | $7.0M | $-7.9M | ||
| Q4 24 | $7.4M | $-4.1M | ||
| Q3 24 | $8.1M | $3.2M | ||
| Q2 24 | $17.6M | $-4.1M | ||
| Q1 24 | $9.3M | $-5.2M |
| Q4 25 | 83.9% | 74.2% | ||
| Q3 25 | 83.5% | 74.4% | ||
| Q2 25 | 81.1% | 75.7% | ||
| Q1 25 | 81.2% | 75.9% | ||
| Q4 24 | 81.8% | 76.3% | ||
| Q3 24 | 81.8% | 77.8% | ||
| Q2 24 | 83.0% | 78.2% | ||
| Q1 24 | 84.7% | 76.2% |
| Q4 25 | 17.8% | -182.2% | ||
| Q3 25 | 19.5% | -3.9% | ||
| Q2 25 | 12.5% | -138.7% | ||
| Q1 25 | 9.4% | -4.7% | ||
| Q4 24 | 11.9% | -1.5% | ||
| Q3 24 | 13.3% | -0.9% | ||
| Q2 24 | 26.9% | -4.6% | ||
| Q1 24 | 15.6% | -3.1% |
| Q4 25 | 12.9% | -178.3% | ||
| Q3 25 | 14.7% | -8.3% | ||
| Q2 25 | 9.8% | -135.2% | ||
| Q1 25 | 8.0% | -10.3% | ||
| Q4 24 | 8.0% | -5.3% | ||
| Q3 24 | 9.6% | 4.1% | ||
| Q2 24 | 20.2% | -5.4% | ||
| Q1 24 | 10.9% | -6.5% |
| Q4 25 | $0.10 | $-1.68 | ||
| Q3 25 | $0.11 | $-0.08 | ||
| Q2 25 | $0.06 | $-1.15 | ||
| Q1 25 | $0.05 | $-0.09 | ||
| Q4 24 | $0.05 | $-0.04 | ||
| Q3 24 | $0.05 | $0.03 | ||
| Q2 24 | $0.12 | $-0.04 | ||
| Q1 24 | $0.06 | $-0.06 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | ||
|---|---|---|
| 現金・短期投資手元流動性 | $166.1M | $115.7M |
| 総負債低いほど良い | $18.0M | $280.1M |
| 株主資本純資産 | $256.5M | $484.4M |
| 総資産 | $342.7M | $1.2B |
| 負債/資本比率低いほどレバレッジが低い | 0.07× | 0.58× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $166.1M | $115.7M | ||
| Q3 25 | $142.1M | $95.7M | ||
| Q2 25 | $118.9M | $162.6M | ||
| Q1 25 | $106.4M | $165.5M | ||
| Q4 24 | $104.4M | $189.5M | ||
| Q3 24 | $88.8M | $168.7M | ||
| Q2 24 | $69.0M | $147.1M | ||
| Q1 24 | $48.5M | $128.3M |
| Q4 25 | $18.0M | $280.1M | ||
| Q3 25 | — | $279.5M | ||
| Q2 25 | — | $279.0M | ||
| Q1 25 | — | $497.6M | ||
| Q4 24 | $19.0M | $496.8M | ||
| Q3 24 | — | $496.2M | ||
| Q2 24 | — | $435.6M | ||
| Q1 24 | — | $434.9M |
| Q4 25 | $256.5M | $484.4M | ||
| Q3 25 | $238.9M | $616.9M | ||
| Q2 25 | $216.6M | $633.7M | ||
| Q1 25 | $202.8M | $755.7M | ||
| Q4 24 | $193.1M | $761.3M | ||
| Q3 24 | $181.0M | $754.7M | ||
| Q2 24 | $168.0M | $815.4M | ||
| Q1 24 | $155.7M | $813.8M |
| Q4 25 | $342.7M | $1.2B | ||
| Q3 25 | $319.0M | $1.3B | ||
| Q2 25 | $291.1M | $1.4B | ||
| Q1 25 | $270.4M | $1.5B | ||
| Q4 24 | $263.9M | $1.6B | ||
| Q3 24 | $243.9M | $1.6B | ||
| Q2 24 | $230.2M | $1.5B | ||
| Q1 24 | $221.7M | $1.5B |
| Q4 25 | 0.07× | 0.58× | ||
| Q3 25 | — | 0.45× | ||
| Q2 25 | — | 0.44× | ||
| Q1 25 | — | 0.66× | ||
| Q4 24 | 0.10× | 0.65× | ||
| Q3 24 | — | 0.66× | ||
| Q2 24 | — | 0.53× | ||
| Q1 24 | — | 0.53× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | ||
|---|---|---|
| 営業キャッシュフロー直近四半期 | $25.0M | $23.3M |
| フリーキャッシュフロー営業CF - 設備投資 | — | $23.2M |
| FCFマージンFCF / 売上 | — | 29.6% |
| 設備投資強度設備投資 / 売上 | — | 0.1% |
| キャッシュ転換率営業CF / 純利益 | 1.64× | — |
| 直近12ヶ月FCF直近4四半期 | — | $90.7M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $25.0M | $23.3M | ||
| Q3 25 | $29.3M | $32.2M | ||
| Q2 25 | $14.4M | $33.1M | ||
| Q1 25 | $5.3M | $2.5M | ||
| Q4 24 | $18.8M | $34.3M | ||
| Q3 24 | $19.6M | $60.1M | ||
| Q2 24 | $21.8M | $31.0M | ||
| Q1 24 | $6.0M | $24.8M |
| Q4 25 | — | $23.2M | ||
| Q3 25 | — | $32.1M | ||
| Q2 25 | — | $33.0M | ||
| Q1 25 | — | $2.4M | ||
| Q4 24 | — | $34.0M | ||
| Q3 24 | — | $59.8M | ||
| Q2 24 | — | $30.5M | ||
| Q1 24 | — | $24.7M |
| Q4 25 | — | 29.6% | ||
| Q3 25 | — | 41.3% | ||
| Q2 25 | — | 43.6% | ||
| Q1 25 | — | 3.0% | ||
| Q4 24 | — | 43.5% | ||
| Q3 24 | — | 75.6% | ||
| Q2 24 | — | 40.7% | ||
| Q1 24 | — | 30.6% |
| Q4 25 | — | 0.1% | ||
| Q3 25 | — | 0.2% | ||
| Q2 25 | — | 0.1% | ||
| Q1 25 | — | 0.2% | ||
| Q4 24 | — | 0.3% | ||
| Q3 24 | — | 0.3% | ||
| Q2 24 | — | 0.6% | ||
| Q1 24 | — | 0.1% |
| Q4 25 | 1.64× | — | ||
| Q3 25 | 1.75× | — | ||
| Q2 25 | 1.50× | — | ||
| Q1 25 | 0.75× | — | ||
| Q4 24 | 2.53× | — | ||
| Q3 24 | 2.42× | 18.52× | ||
| Q2 24 | 1.24× | — | ||
| Q1 24 | 0.65× | — |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
MDXG
| Wound | $78.7M | 67% |
| Surgical | $39.4M | 33% |
RPAY
| Sales Channel Directly To Consumer | $69.4M | 88% |
| Other | $6.8M | 9% |
| Sales Channel Through Intermediary | $2.3M | 3% |